Imperia Online Quiz October'2018
Imperia Online Quiz October'2018
- 1.
How is Diabetes Mellitus linked to AF-stroke risk
- A.
Diabetes causes AF
- B.
Diabetes causes stroke
- C.
Diabetes is an important component of CHA2DS2VaSc score
- D.
Diabetes is a component of HASBLED score
Correct Answer
C. Diabetes is an important component of CHA2DS2VaSc score -
- 2.
Diabetics who suffer stroke demonstrate ___________ vs the non diabetics:
- A.
More severe residual diasability, increased long term mortality
- B.
Less severe residual diasability, increased long term comorbidity
- C.
Severe Gastrointestinal adverse effects
- D.
None of the above
Correct Answer
A. More severe residual diasability, increased long term mortality -
- 3.
Clot Case Series Issue 9 talks about which of the following topics:
- A.
Use of Dabigatran in patient not responding to Warfarin
- B.
Use of Dabigatran as preferred NOAC for SPAF
- C.
Use of Dabigatran in patient with AF in coronary artery disease
- D.
None of the above
Correct Answer
C. Use of Dabigatran in patient with AF in coronary artery disease -
- 4.
Out of 18,113 patients recruited in RELY trial, Diabetes Mellitus was reported in___ patients
- A.
4221
- B.
4412
- C.
4422
- D.
4421
Correct Answer
A. 4221 -
- 5.
Diabetes Mellitus patients showed following characteristics in sub analysis of RELY trial:
- A.
Stroke or Systemic embolism was more common in DM patients
- B.
Increased risk of death and major bleeding
- C.
Both a & b
- D.
None of the above
Correct Answer
C. Both a & b -
- 6.
What are the common risk factors for AF and CAD:
- A.
Hypertension, DM, sleep apnea, Obsetity
- B.
Inflammation
- C.
Smoking
- D.
All of the above
Correct Answer
D. All of the above -
- 7.
The study done to evaluate effectiveness of dabigatran in patients undergoing PCi is
- A.
REDUAL PCI
- B.
RESIDUAL PCI
- C.
REMEDIAL PCI
- D.
None of the above
Correct Answer
A. REDUAL PCI -
- 8.
In REDUAL PCI trial: the two groups received triple therapy consisting of ____ and dual therapy consisting of ____
- A.
Warfarin + Aspirin + Clopidogrel or Ticagrelor, Dabigatran 110/50mg + Clopidogrel or Ticagrelor
- B.
Dabigatran 110mg + Aspirin + Clopidogrel or Ticagrelor, Warfarin + Aspirin
- C.
Warfarin + Aspirin + Clopidogrel or Ticagrelor, Dabigatran 110/150mg + Aspirin
- D.
Warfarin + Aspirin + Clopidogrel or Ticagrelor, Dabigatran 110/50mg + Aspirin + Clopidogrel or Ticagrelor
Correct Answer
A. Warfarin + Aspirin + Clopidogrel or Ticagrelor, Dabigatran 110/50mg + Clopidogrel or Ticagrelor -
- 9.
REDUAL PCI trial involed
- A.
2725 adult patients from 40 countries
- B.
2775 adult patients from 80 countries
- C.
2375 adult patients from 40 countries
- D.
2375 adult patients from 80 countries 2375 adult patients from 80 countries 2375 adult patients from 80 countries 2375 adult patients from 80 countries
Correct Answer
A. 2725 adult patients from 40 countries -
- 10.
As per REDUAL PCI trial, Dabigatran can be used in AF patients with CAD who have undergone PCI because:
- A.
Dabigatran significantly lowers bleeding events and is non inferior to triple therapy
- B.
Dabigatran + Clopidogrel significantly lowers bleeding events and is non inferior to triple therapy
- C.
Dabigatran + Clopidogrel significantly lowers stroke risk and is non inferior to triple therapy
- D.
Dabigatran significantly lowers stroke risk and is non inferior to triple therapy
Correct Answer
B. Dabigatran + Clopidogrel significantly lowers bleeding events and is non inferior to triple therapy -
- 11.
ACCF/AHA 2013 recommends Ezuric (Eplerenone) in patients with ________
- A.
NYHA class III-IV and LVEF of
- B.
NYHA class III-IV and LVEF of
- C.
NYHA class II-IV and LVEF of
- D.
NYHA class II-IV and LVEF of
Correct Answer
C. NYHA class II-IV and LVEF of -
- 12.
Ezuric is better than ________ due to lesser incidences of adverse effect, better half-life and more no. of patients showing benefits
- A.
ARBs and ACE inhibitors
- B.
Spironolactone
- C.
Beta blockers
- D.
None of the above
Correct Answer
B. Spironolactone -
- 13.
Ezuric is indicated ________
- A.
In Acute coronary syndrome
- B.
In Stage I hypertension
- C.
In Post MI CHF patients
- D.
In Nocturnal Hypertension
Correct Answer
C. In Post MI CHF patients -
- 14.
In EPHESUS survival study, Eplerenone was compared with _______
- A.
Placebo
- B.
Spironolactone
- C.
Both Placebo & Spironolactone
- D.
None of above
Correct Answer
A. Placebo -
- 15.
As per EMPHASIS-HF study, Ezuric (Eplerenone) reduces the _______
- A.
Risk of death
- B.
Risk of hospitalization due to HF
- C.
Both a & b
- D.
D) Neither a nor b
Correct Answer
C. Both a & b -
- 16.
In EMPHASIS-HF, Incidence of Gynecomastia with the use of Eplerenone was seen in _______ % of patients which was less than placebo.
- A.
1%
- B.
43%
- C.
0.7%
- D.
35%
Correct Answer
C. 0.7% -
- 17.
ISDN plus Hydralazine combination is approved by USFDA to manage heart failure.
- A.
True
- B.
False
Correct Answer
A. True -
- 18.
MUZIKA reduces rate of first hospitalization due to heart failure by ______ % compared to placebo.
- A.
33
- B.
42
- C.
43
- D.
35
Correct Answer
A. 33 -
- 19.
Number of Effort driven conversions expected per ME for Ezuric and Muzika are ___
- A.
5
- B.
10
- C.
20
- D.
25
Correct Answer
B. 10 -
- 20.
October month input for Ezuric and Muzika is ___
- A.
Paper Weight
- B.
Chit Pad
- C.
Prescription Pad
- D.
None of above
Correct Answer
C. Prescription Pad -
Quiz Review Timeline +
Our quizzes are rigorously reviewed, monitored and continuously updated by our expert board to maintain accuracy, relevance, and timeliness.
-
Current Version
-
Mar 20, 2022Quiz Edited by
ProProfs Editorial Team -
Oct 22, 2018Quiz Created by
ZilokemCT
Back to top